The prevalence of HBP (65.3%), CVD (59.2%), and dyslipidemia (43.7%) reflects the need for novel beneficial CV therapeutic agents, such as GLP-1 RAs and SGLT-2i [8]. This evidence concerns the gene GCG and metabolic syndrome.